ERBB2 and colorectal carcinoma: Nonetheless, HER2-amplified CRC often exhibits a more aggressive biology with chemotherapy resistance and intracranial metastasis, leading to treatment failures and resistance.17 Chemotherapy resistance has been reported among patients with HER2-amplified CRC, indicating that more advanced research is needed to improve outcomes for this patient population.18 Currently, precision therapeutics are being investigated as first-line treatments to deliver targeted therapy early in the disease course (NCT05253651; MOUNTAINEER-03).